Medicine Matters rheumatology

Philip Robinson discusses why TNF inhibitors may be a favorable treatment option for COVID-19 and outlines the trials that are currently underway.

Cristina Mussini discusses the current data on interleukin inhibitors for the treatment of COVID-19 and explores why tocilizumab has been associated with beneficial outcomes in some studies but not others.

Marwan Bukhari talks about the rationale behind investigating baricitinib and other JAK inhibitors for the treatment of COVID-19 and outlines the current efficacy data.

In this series of podcasts we are speaking to the experts about repurposing rheumatology drugs for the treatment and prevention of COVID-19.

In this episode, Alfred (Al) Kim, a rheumatologist from the Washington University School of Medicine in St Louis, Missouri, USA, talks about hydroxychloroquine. He discusses why the drug was initially considered promising but later shown to be ineffective, and describes the impact drug shortages have had on rheumatology practice.

Find more on Medicine Matters rheumatology

In this series of podcasts we are speaking to the experts about repurposing rheumatology drugs for the treatment and prevention of COVID-19.

For the introductory podcast, Jinoos Yazdany, rheumatologist and Professor of Medicine at the University of California, San Francisco in the USA, talks about the rationale behind investigating these agents and the role of rheumatologists in ensuring they are studied as safely and efficiently as possible.

Find more on Medicine Matters rheumatology

In April 2020, the American College of Rheumatology issued guidance for the management of people with rheumatic diseases during the COVID-19 pandemic.

We spoke to lead author Ted Mikuls, from the University of Nebraska Medical Center in the USA, to find out more about what rheumatologists should do to best care for their patients in light of COVID-19, and what some of the unanswered questions are.

Find more on Medicine Matters rheumatology

Image credit: COVID-19 illustration © koto_feja/Getty Images/iStock

Philip Robinson, chair of the steering committee for the COVID-19 Global Rheumatology Alliance, tells us about the initiative that will enable rheumatologists to document their patient experiences of COVID-19 and contribute to a shared learning resource (17:28).

Find more on Medicine Matters rheumatology

Image credit: COVID-19 illustration © koto_feja/Getty Images/iStock

Sangeeta Sule, from Children’s National Hospital in Washington, DC, USA, shares her experience of how the pediatric rheumatology community is adapting to the COVID-19 pandemic, including the use of telemedicine practice.

Find more on Medicine Matters rheumatology

Kevin Winthrop, from Oregon Health & Science University in Portland, USA, discusses why patients with rheumatic diseases may be vulnerable to COVID-19 and how different treatments may affect the risk for infection and prognosis of the disease.

Find more on Medicine Matters rheumatology

In the second of a two-part series, Dafna Gladman, Philip Mease, and Oliver FitzGerald discuss the implications and limitations of the recent ACR–NPF guidelines for the management of psoriatic arthritis, together with key clinical trials that have been published since the guidelines were released.

Listen to part 1 here

Find more on Medicine Matters rheumatology